|24 November 2015 (midnight CET)*||Regular abstract submission deadline|
|22 January 2016||Abstract notification to authors|
|03 February 2016||Final day to withdraw accepted abstracts and/or to request modifications of titles and author lists|
|15 February 2016||Late breaker submission opens**|
|24 February 2016 (midnight CET)*||Late breaker submission ends|
|11 March 2016
||Late breaker abstract notification|
*No abstracts will be accepted after the stated submission deadline.
**There is an EUR 121.00 non-refundable fee (21% VAT included) for submitting a late breaker abstract.
If you have questions regarding abstracts or need assistance, please contact the abstract team at ILC.email@example.com.
Abstract hotline: +41 (0)22 807 29 75 (CET office hours)
After having submitted your abstract, you will receive a confirmation by e-mail with your abstract reference number.
If you do not receive a confirmation e-mail please contact the abstract team ILC.firstname.lastname@example.org.
Should you wish to make corrections to an already submitted abstract, or if you wish to submit other abstracts later, you may use your personal access codes. Corrections to regular abstracts can only be made up to the submission deadline: 24 November 2015. Corrections to late-breaker abstracts can only be made up to the late-breaker submission deadline: 24 February 2016.
If an abstract is accepted, the person designated as the presenting author must attend the congress to present the data in person. Acceptance of the abstract implies payment of the registration fee by the presenting author.
Abstracts may only be submitted via Internet. Abstracts submitted by fax or email will not be accepted.
All abstracts must be submitted and presented in English. Please use UK English spelling and have your abstract proofread for grammar and syntax.
Abstracts that have previously been presented in non-EASL International Gastroenterology/Hepatology meetings will NOT be accepted. Please ensure that your abstract has never been presented before. If this rule is not respected, the abstract will be rejected, and will not be considered.
Exception: Any abstract submitted to a 2015 or 2016 EASL Event (Monothematic or Special conference) may be resubmitted and will be considered for presentation at The International Liver Congress™ 2016. Please note that acceptance of the abstract at an EASL Event does not automatically imply acceptance at the ILC.
Abstract topic: Please choose from the 27 topics available. Carefully select the adequate topic for your abstract submission. Misplaced abstracts may be rejected. Abstracts relating to the same study should not be split and submitted in the same topic category.
Clinical Trials in Progress: Please only submit to this abstract category for trials that are not yet completed, and are in the recruitment phase. This category is not for abstracts with preliminary data.
Title: The title of your abstract should be precise and explicit. The number of characters in your title should be between 50 and 250 maximum.
Authors: Please list all authors with their affiliations (institution, city and country). Email addresses can be indicated, in which case the co-author will be notified of the abstract submission.
Authors’ disclosures: All authors must disclose their conflict of interests. If your research has been granted any commercial or institutional support, you will be asked to disclose this during the submission process.
Authorship: Credit for authorship requires substantial contributions to the conception and design; or the acquisition, analysis, or interpretation of the data, final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.
Abstract body: Abstracts should be between 500 and 2,500 characters including spaces (excluding title and authors). Do not use abbreviations, footnotes or references in the abstract.
You should structure your abstract using the following headings:
Drugs and chemicals: Generic names of drugs and chemicals should be provided. If trademarks are mentioned, the manufacturer’s name and city should also be given. All funding sources supporting the work, either public or private, especially those from pharmaceutical companies, must be provided.
Keywords: A maximum of 5 keywords can be added to your submission.
By submitting an abstract to the ILC 2016 you agree with the statement below.
I hereby assign to the European Association for the Study of the Liver (EASL) the copyright in the abstract identified above (government authors not electing to transfer agree to assign an exclusive publishing and distribution license) and any supplemental tables, illustrations or other information submitted therewith that are intended for publication as part of the abstract in all forms and media (whether now known or hereafter developed), throughout the world, in all languages, for the full term of copyright, effective when and if the article is accepted for publication. This transfer includes the right to provide the abstract in electronic and online forms and systems.
The presenting author of an accepted abstract must attend and register for the congress. All accepted abstracts will be published in a Supplement of the Journal of Hepatology.
Requests for withdrawal of an abstract must be received in writing to ILC.email@example.com by 3 February 2016 to avoid publication in the Journal of Hepatology supplement and final programme.
A large quantity of abstracts, including some late-breaker abstracts, will be published on the ILC 2016 website and ILC app ahead of the congress showing abstract title, author’s names and abstract data.
A smaller quantity of abstracts will be retained and presented during the official EASL Press Office activities and/or in official EASL Press Office materials. These abstracts are under embargo and embargoed abstract titles, authors and institute names will be made available on the congress website, but related data will only be released during the congress.
Read the ILC 2016 embargo policy.